Structured evidence table for Calcium Bone Density Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Calcium Bone Density Randomized Trial | Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Density Randomized Trial | 18 A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Density Randomized Trial | The present review builds upon this foundation by contextualizing historical data and synthesizing subsequent evidence across 3 domains: (1) pharmacology and mechanisms; (2) established and preventive osteoporosis; and (3) acute orthopaedic applications, with particular emphasis on analgesia and time-dependent therapeutic effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Density Randomized Trial | 1 3 - 4 5 , Intranasal salmon calcitonin (IN-CAL) is a peptide antiresorptive agent historically used in the management of postmenopausal osteoporosis, where early randomized trials demonstrated lumbar spine-specific increases in bone mineral density (BMD) with minimal peripheral effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Density Randomized Trial | 3 3 4 4 More than 50 bone replacements have been crafted since Van Meekren’s initial bone transplant in 1668, but none have found extensive therapeutic use. | 4 | Ramesh Konathala SV (2026) | Eggshell sourced hydroxyapatite as a bone regenerative material in dentistry – a narrative review |
| Calcium Bone Density Randomized Trial | Instead of commercial grafts, eggshell-derived hydroxyapatite (EHA) has recently demonstrated better osteoconductive qualities and increased bone healing in rats. | 4 | Ramesh Konathala SV (2026) | Eggshell sourced hydroxyapatite as a bone regenerative material in dentistry – a narrative review |
| Calcium Bone Density Randomized Trial | (2019) [] RCT, split mouth Socket preservation 12 EnHA Placebo, no graft Increased bone density after 6 months 3 Nainoor et al. | 4 | Ramesh Konathala SV (2026) | Eggshell sourced hydroxyapatite as a bone regenerative material in dentistry – a narrative review |
| Calcium Bone Density Randomized Trial | 1 2 Bone is a dynamic connective tissue, and bone regeneration is a complex, well-orchestrated physiological process that has the intrinsic capacity to repair in response to injury. | 4 | Ramesh Konathala SV (2026) | Eggshell sourced hydroxyapatite as a bone regenerative material in dentistry – a narrative review |
Source documents